News
PFE
26.20
-0.47%
-0.13
March Readers Marked 20 Ideal-To-Buy Dividend Dogs
Home Dividends Analysis Dividend Quick Picks March Readers Marked 20 Ideal-To-Buy Dividending Dogs. Of the 32 stocks mentioned by Fly_dragonfly in their comments, 20 qualified as "ideal" for dividend-paying stocks. Two stocks made the top 20 list for the month of March.
Seeking Alpha · 5h ago
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Moderna Inc. Is set to clash with Pfizer Inc. And BioNTech SE in a pivotal London patent trial concerning the development of COVID-19 vaccines. Moderna alleges patent infringement by its competitors in utilizing the mRNA platform crucial to vaccine development. The trial is slated to take place in London.
Benzinga · 20h ago
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise gets EU orphan drug status for muscular dystrophy drug. Edgewise Therapeutics has received orphan drug designation from EU regulators for its drug candidate sevasemten. The drug candidate is in the treatment of Becker muscular dy Strophy and Duchenne muscular dystrophy.
Seeking Alpha · 1d ago
Baron Health Care Fund Q1 2024 Shareholder Letter
Baron Health Care Fund advanced 8.92% in the quarter ended March 31, 2024. The Fund's performance was in line with the Russell 3000 Health Care Index and the S&P 500 Index. Investments in health care equipment, pharmaceuticals, and life sciences added the most value in the period.
Seeking Alpha · 1d ago
Better Buy: Pfizer vs. Viking Therapeutics
Pfizer and Viking Therapeutics offer a rock-bottom valuation and a sky-high dividend yield. Pfizer's shares offer the highest yield among big pharma stocks. The company's stock is less risky, offers a substantial yield, and is priced attractively. Viking has emerged as a top growth stock thanks to its weight-loss candidate.
The Motley Fool · 1d ago
Pfizer vs Moderna battle over COVID vaccine patents begins in UK
Pfizer vs Moderna battle over COVID vaccine patents begins in UK. Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19. Moderna says Pfizer copied its technology before the pandemic began.
Reuters · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), Pfizer (PFE) and Cardinal Health (CAH)
TipRanks · 1d ago
Pfizer (PFE) Rises Higher Than Market: Key Facts
NASDAQ · 1d ago
After Hours Most Active for Apr 22, 2024 : CORZ, CSCO, HBAN, T, KMI, PFE, UBER, PTEN, PAGP, FOLD, NEE, EQT
NASDAQ · 1d ago
Goldman’s debt issuers stocks basket
Seeking Alpha · 1d ago
Sanofi reportedly settles 4K Zantac cases for $100M
Healthcare Sanofi reportedly settles 4K Zantac cases for $100M. Under the settlement, Sanofi will pay around $25,000 per claim. The suits alleged that Sanofi failed to adequately warn consumers about the safety of its heartburn drug. The drug was pulled off the market in 2019 over concerns it could produce a carcinogen.
Seeking Alpha · 1d ago
Dividend yield and growth stock list by Goldman
Goldman Sachs analysts expect stock dividends to grow by more than 6% this year. Dividend growth accelerated in the second half of last year, and analysts expect strong growth in 2024 and 2025. Large-cap technology firms like Salesforce and eBay started dividends during the fourth quarter.
Seeking Alpha · 2d ago
EU regulators approve Pfizer antibiotic Emblaveo
EU regulators approve Pfizer antibiotic Emblaveo for the treatment of serious infections due to Gram-negative bacteria. The drug is a combination of the drugs aztreonam and avibactam. AbbVie holds commercial rights to the product in the US and Canada.
Seeking Alpha · 2d ago
EUROPEAN COMMISSION APPROVES PFIZER’S EMBLAVEO® FOR PATIENTS WITH MULTIDRUG-RESISTANT INFECTIONS AND LIMITED TREATMENT OPTIONS
Reuters · 2d ago
Dividend Income Summary: Lanny's March 2024 Summary
Lanny's March 2024 dividend income total was $5,888.56. The S&P 500 is already up 6% in 2024. Dividend investing allows you to earn the best passive income stream. Lanny and his wife made $10,000+ in a single month in March.
Seeking Alpha · 2d ago
Weekly Report: what happened at PFE last week (0415-0419)?
Weekly Report · 2d ago
What's Next For Johnson & Johnson Stock After Beating Q1 Earnings?
NASDAQ · 2d ago
13 new obesity drugs could hit the market by 2029 amid surging demand
13 new obesity drugs could hit the market by 2029 amid surging demand for the products in the U.S. World Health Organization predicts 50% of US adults will be considered obese by 2030. Sales of weight-loss drugs have soared, with Novo Nordisk and Eli Lilly generating $9.7B in 2023.
Seeking Alpha · 2d ago
Goldman picks top capex and R&D stocks
Goldman Sachs expects capex and R&D growth to slow to 7% this year, down from 10% in 2023. Sales growth is the largest driver of capex growth in Goldman's model. The mega-cap tech stocks are committed to investing in AI. The top 10 firms with the largest capex spending are expected to be in the S&P 500.
Seeking Alpha · 2d ago
Some Bubbles Are Starting To Pop
The S&P 500 posted its worst weekly performance since March of 2023 this week. The yield on the 10-Year Treasury has risen to 4.62% from 3.9% in late February. Bubbles in the AI sector and high beta parts of the market are deflating. Rising interest rates are also impacting the commercial real estate sector.
Seeking Alpha · 3d ago
More
Webull provides a variety of real-time PFE stock news. You can receive the latest news about Pfizer through multiple platforms. This information may help you make smarter investment decisions.
About PFE
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.